Catalyst Pharmaceuticals, Inc.
CPRX US
CPRX USCatalyst Pharmaceuticals, Inc.
United States Composite15.12
- Business
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Company News
Jim Cramer recommends five small-cap health-care stocks
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
Analysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Analysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
‘Time to Hit Buy,’ Says Bank of America About These 3 Stocks
Here are Thursday's biggest analyst calls: Nvidia, Tesla, Apple, Micron, Rivian, Amazon, Deere, UnitedHealth & more
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference